$NUOX · NuvOx Therapeutics, Inc.
NuvOx Therapeutics filed Amendment No. 3 to its S-1 registration statement for an IPO of 2,860,000 shares at an estimated price range of $6.00 to $8.00 per share, with a 45-day underwriter over-allotment option for up to 429,000 additional shares. The company intends to list on NYSE American under the symbol "NUOX." Proceeds are earmarked to complete ongoing Phase IIb trials in GBM and stroke, a planned Phase II ARDS trial, and preparation for a pivotal Phase III GBM trial.
- Proposed IPO of 2,860,000 shares at $6.00–$8.00 per share, targeting $17.2M–$22.9M in gross proceeds.
- NanO₂ is a clinical-stage oxygen therapeutic targeting acute ischemic stroke, GBM, ARDS, and sickle cell anemia.
- Phase IIb GBM trial fully enrolled at 93 patients; Phase IIb UK stroke trial has treated 27 of 150 planned patients.
- Phase Ib respiratory distress trial completed first two cohorts (15 patients); Phase II ARDS trial approved by Health Canada.
- NanO₂ holds FDA orphan drug designation for GBM (2015) and sickle cell anemia (2016).
Price data unavailable.
A clinical-stage biotech with three active trials and two orphan drug designations is testing whether an IPO can fund its pipeline through Phase II and into pivotal Phase III, despite no approved products or revenue.
Joins a wave of clinical-stage biotechs targeting hypoxia-related indications — a space with multiple high-profile neuroprotective failures. Orphan drug designations provide some exclusivity runway but no guarantee of commercial viability.
Pre-revenue clinical-stage biotech with no approved products; 49 SAEs in the ongoing Phase IIb GBM trial, including two possibly related to NanO₂. No assurance Phase II/III trials will succeed or that IPO proceeds will fully fund them. No prior public market for the stock.